Easier scheduling, transportation, and virtual care can get patients to the doctor, but they need clearer guidance on when to seek screenings or telehealth.
Food and beverage brands can tailor protein benefits to GLP-1 users, athletes, and others with higher protein needs.
New Mexico’s $942M order tests whether courts can require product changes alongside financial penalties.
As brands strive to create lasting connections with interested consumers, Playtex Sport is counting on active creators to reach those who will care the most and drive sales to retailers.
Hims & Hers adds doctor-backed AI guidance for women’s weight loss members, underscoring that AI convenience and care quality are emerging as critical competitive advantages beyond GLP-1 access.
Gen Z turns to YouTube, while millennials to Facebook—underscoring the need for social content that helps consumers parse GLP-1 options.
The FDA decision reinforces the need for clinical evidence, but approval alone won't drive adoption.
Novo's Wegovy pill gains failed to offset declines in injectable sales. Investors continue to favor companies like Lilly with broader drug pipelines despite a positive outlook for GLP-1 pills.
CPG brands such as P&G are betting consumers won't cut back on wellness spending, favoring premium supplements like Thorne’s over cheaper alternatives.
Half of US podcast listeners consume health podcasts, giving health and pharma brands opportunities to tailor messaging to audiences interested in fitness, nutrition, or specific health conditions.
Their “always online” presence means they encounter a steady stream of health information. Simple, evidence-backed wellness claims align with their health goals.
A tie-up could create a cancer powerhouse, but regulators would likely require divestitures.
Pharma marketers should use point-of-care messaging and practical education on treatment options to help adults 50+ initiate discussions with their physicians.
An experimental heart drug missed a key clinical trial result, delivering a blow to Novo Nordisk as it looks to expand beyond GLP-1s.
Its flagship Botox brand lifted its otherwise underwhelming aesthetics results, while Juvederm results show perceptions about fillers remain a tougher hurdle to overcome.
Brands can better connect with younger audiences by treating healthy habits and indulgences as compatible parts of self care.
Telehealth's easy-to-sign-up, hard-to-cancel subscription practice is now a regulatory liability.
Our updated forecasts show that genAI, social, and streaming are becoming the front lines where pharma must build trust and visibility.
Such financial sacrifices underscore relentless demand despite high costs.
Doctronic's Summer Health deal extends AI care to families seeking urgent virtual care, but clear guardrails on when clinician escalation is required will matter as much as convenience.